Sunday, March 29, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Optum and MarinHealth form strategic partnership

MarinHealth Medical Center has become the latest health system to form a strategic relationship with Optum, announcing a partnership to advance its operational objectives in the revenue cycle and facilitate the patient experience for people living in Marin County, California.

Optum and MarinHealth will focus on operational efficiency for the health system, the organizations said. To do this, MarinHealth will employ Optum technology to streamline nonclinical administrative processes and simplify experiences for patients and providers. Optum also will provide revenue cycle management services and supporting technologies.

MarinHealth hopes the relationship will equip it with the necessary tools and resources to improve business processes and enhance infrastructure. Its goal is to remain an independent health system, with the newfound operational and administrative support allowing doctors and nurses to focus more on patient care.

Source: Healthcare Finance

https://www.healthcarefinancenews.com/news/optum-and-marinhealth-form-strategic-partnership

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!